[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 48 of about 48
1. Nieder C, Astner ST, Molls M, Grosu AL: Analysis of long-term survivors of glioblastoma multiforme in a single institution with aggressive local retreatment protocol. Anticancer Res; 2007 Jul-Aug;27(4C):2993-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of long-term survivors of glioblastoma multiforme in a single institution with aggressive local retreatment protocol.
  • Current treatment methods result in survival beyond 2 years in just a minority of adult patients with glioblastoma multiforme (GBM).
  • Patients with oligodendroglial component or progression from low-grade glioma were not included.
  • All were younger than 60 years, had a good performance status, RPA class III or IV and a long interval to relapse.
  • Those with the longest survival times had also received two different chemotherapy regimens.
  • However, two of the patients were never treated with chemotherapy.
  • CONCLUSION: When selecting patients on the basis of the factors associated with long-term survival, the same sequence of surgery, radiotherapy and chemotherapy that should be considered at first diagnosis might provide a moderate survival extension.
  • [MeSH-major] Glioblastoma / therapy. Supratentorial Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Female. Humans. Male. Middle Aged. Nimustine / administration & dosage. Retrospective Studies. Teniposide / administration & dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695484.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0S726V972K / Nimustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 957E6438QA / Teniposide
  •  go-up   go-down


2. Broniscer A, Gajjar A: Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist; 2004;9(2):197-206
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist.
  • Pediatric high-grade gliomas represent a heterogeneous group of tumors that accounts for 15%-20% of all pediatric central nervous system tumors.
  • These neoplasms predominantly involve the supratentorial hemispheres or the pons, in which case the tumors are usually called diffuse brainstem gliomas.
  • The diagnosis of supratentorial neoplasms is dependent on their histologic appearance.
  • Older children (>3 years) with supratentorial neoplasms undergo a multimodality treatment comprised of surgical resection, radiation therapy, and chemotherapy.
  • The addition of chemotherapy seems to improve the survival of a subset of these children, particularly those with glioblastoma multiforme.
  • However, 2-year survival rates remain poor for children with supratentorial neoplasms, ranging from 10%-30%.
  • Radiation therapy is the mainstay of treatment for children with diffuse brainstem gliomas.
  • The role of chemotherapy for these children is not clear, and it is, in general, employed in the context of an investigational study.
  • Because the outcome for patients with either type of tumor is poor when standard multimodality therapy is used, these children are ideal candidates for innovative treatment approaches.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / therapy. Glioma / genetics. Glioma / therapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Astrocytoma / physiopathology. Astrocytoma / therapy. Brain Stem Neoplasms / genetics. Brain Stem Neoplasms / physiopathology. Brain Stem Neoplasms / therapy. Child. Disease Progression. Humans. Prognosis. Treatment Outcome


3. Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS: Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol; 2001 10;3(4):246-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
  • On the basis of preclinical evidence of synergism between Gliadel wafers and TEMO, a phase I study was designed to evaluate the toxicity of combining these 2 agents in the treatment of patients with recurrent supratentorial malignant glioma.
  • All patients had surgical resection of the tumor at relapse, and up to 8 Gliadel (3.85%) wafers were placed in the surgical cavity following resection.
  • Patients with stable disease or response after the first cycle of TEMO were allowed to continue treatment at the same dose every 4 weeks for 12 cycles or until disease progression or unacceptable toxicity.
  • There were 7 patients with glioblastoma multiforme and 3 patients with anaplastic astrocytoma.
  • The treatment was well tolerated, with only 1 patient suffering grade III thrombocytopenia at the highest dose level.
  • Two patients at each dose level had no evidence of disease progression after treatment.
  • Four patients suffered progressive disease on therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Carmustine / administration & dosage. Glioblastoma / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Disease Progression. Dose-Response Relationship, Drug. Drug Implants. Drug Synergism. Female. Humans. Magnetic Resonance Imaging. Male. Maximum Tolerated Dose. Middle Aged. Safety. Thrombocytopenia / chemically induced. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11584894.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Implants; 7GR28W0FJI / Dacarbazine; U68WG3173Y / Carmustine; YF1K15M17Y / temozolomide
  • [Other-IDs] NLM/ PMC1920622
  •  go-up   go-down


Advertisement
4. Mizumoto M, Tsuboi K, Igaki H, Yamamoto T, Takano S, Oshiro Y, Hayashi Y, Hashii H, Kanemoto A, Nakayama H, Sugahara S, Sakurai H, Matsumura A, Tokuuye K: Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys; 2010 May 1;77(1):98-105
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme.
  • PURPOSE: To evaluate the safety and efficacy of postoperative hyperfractionated concomitant boost proton radiotherapy with nimustine hydrochloride for supratentorial glioblastoma multiforme (GBM).
  • METHODS AND MATERIALS: Twenty patients with histologically confirmed supratentorial GBM met the following criteria:.
  • Magnetic resonance imaging (MRI) T(2)-weighted high area (clinical tumor volume 3 [CTV3]) was treated by x-ray radiotherapy in the morning (50.4 Gy in 28 fractions).
  • [MeSH-major] Glioblastoma / radiotherapy. Protons / therapeutic use. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy / methods. Dexamethasone / therapeutic use. Dose Fractionation. Female. Glucocorticoids / therapeutic use. Humans. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Nimustine / therapeutic use. Prednisolone / therapeutic use. Radiation Injuries / drug therapy. Survival Rate. Tumor Burden

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19695794.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; 0 / Protons; 0S726V972K / Nimustine; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


5. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M: A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys; 2006 Aug 1;65(5):1422-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023.
  • PURPOSE: This phase II trial was performed to assess the feasibility, toxicity, and efficacy of dose-intense accelerated radiation therapy using weekly fractionated stereotactic radiotherapy (FSRT) boost for patients with glioblastoma multiforme (GBM).
  • METHODS AND MATERIALS: Patients with histologically confirmed GBM with postoperative enhancing tumor plus tumor cavity diameter <60 mm were enrolled.
  • A 50-Gy dose of standard radiation therapy (RT) was given in daily 2-Gy fractions.
  • In addition, patients received four FSRT treatments, once weekly, during Weeks 3 to 6.
  • FSRT dosing of either 5 Gy or 7 Gy per fraction was given for a cumulative dose of 70 or 78 Gy in 29 (25 standard RT + 4 FSRT) treatments over 6 weeks.
  • Toxicity included: 3 Grade 4 chemotherapy, 3 acute Grade 4 radiotherapy, and 1 Grade 3 late.
  • The median survival time was 12.5 months.
  • Patients with gross total resection (41%) had a median survival time of 16.6 months vs. 12.0 months for historic controls with gross total resection (p = 0.14).
  • [MeSH-major] Glioblastoma / surgery. Radiosurgery / methods. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Feasibility Studies. Female. Humans. Male. Middle Aged. Radiotherapy, Conformal / methods. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750317.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


6. Bay JO, Linassier C, Biron P, Durando X, Verrelle P, Kwiatkowski F, Rosti G, Demirer T, EMBT solid tumors working party: Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study. Int J Cancer; 2007 Apr 15;120(8):1782-6
Hazardous Substances Data Bank. Carmustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study.
  • Radiotherapy plus concomitant and adjuvant temozolomide have demonstrated improved survival for glioblastoma.
  • High-doses chemotherapy with carmustine is another way to improve response and survival by increasing the dose delivered.
  • European Group for Blood and Marrow Transplantation experience of this treatment in patients with high-grade glioma was reported here.
  • Forty-eight to 72 hr after chemotherapy, 108 patients received autologous hematopoietic stem cells from bone marrow harvest and 109 patients autologous hematopoietic stem cells from peripheral blood.
  • Ten deaths were related to the treatment.
  • Of the 121 patients evaluable for tumor response, 64 (53%) presented an objective response.
  • Median overall survival was 20 months and median time to treatment failure was 7 months.
  • Overall survival and time to treatment were correlated with age, quality of resection and histological subtypes.
  • In glioblastoma multiforme, age and surgery quality appeared to be prognostic factors.
  • 's recent study, this study did not favor high-dose carmustine for patients with glioblastoma multiforme with complete surgical resection.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Carmustine / administration & dosage. Glioblastoma / mortality. Supratentorial Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Oligodendroglioma / therapy. Prognosis. Retrospective Studies. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • [ErratumIn] Int J Cancer. 2007 Nov 15;121(10):2355. Jacques-Olivier, Bay [corrected to Bay, Jacques-Olivier]; Claude, Linassier [corrected to Linassier, Claude]; Pierre, Biron [corrected to Biron, Pierre]; Xavier, Durando [corrected to Durando, Xavier]; Pierre, Verrelle [corrected to Verrelle, Pierre]; Fabrice, Kwiatkowski [corrected to Kwiatkowski, Fabrice]; Giovanni, Rosti [corrected to Rosti, Giovanni]; Taner, Demirer [corrected to Demirer, Taner]
  • (PMID = 17230505.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; U68WG3173Y / Carmustine
  •  go-up   go-down


7. Ushio Y, Kochi M, Hamada J, Kai Y, Nakamura H: Effect of surgical removal on survival and quality of life in patients with supratentorial glioblastoma. Neurol Med Chir (Tokyo); 2005 Sep;45(9):454-60; discussion 460-1
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of surgical removal on survival and quality of life in patients with supratentorial glioblastoma.
  • The relationship between the extent of tumor resection and the progression-free survival, overall survival, and quality of life was evaluated retrospectively in 105 consecutive adult patients with supratentorial hemispheric glioblastoma not primarily involving the basal ganglia, thalamus, or hypothalamus.
  • All patients underwent multidisciplinary treatment including tumor removal and postoperative adjuvant therapy in prospective randomized trials designed to test several chemotherapy regimens.
  • Magnetic resonance imaging with contrast medium was used to determine the extent of tumor resection.
  • Progression- free survival was significantly longer in the GTR group (median survival time [MST] 10.3 months) than in the PR (MST 5.2 months) and the biopsy groups (MST 3.6 months).
  • GTR prolongs the survival of patients with glioblastoma compared to PR or biopsy.
  • [MeSH-major] Glioblastoma / physiopathology. Glioblastoma / surgery. Neurosurgical Procedures. Quality of Life. Supratentorial Neoplasms / physiopathology. Supratentorial Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16195644.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


8. Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL: A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol; 2002 10;4(4):261-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.
  • Temozolomide is a novel second-generation oral alkylating agent with demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA).
  • Fifty-seven patients (51 adult, 6 pediatric) with newly diagnosed supratentorial GBM or AA were treated with temozolomide (200 mg/m ( 2 ) per day for 5 consecutive days every 28 days) for a maximum of 4 cycles.
  • This pre-irradiation treatment approach appears promising, but will require additional evaluation in comparative studies.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Glioma / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Multicenter Studies as Topic. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12356356.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  • [Other-IDs] NLM/ PMC1920664
  •  go-up   go-down


9. Langer CJ, Ruffer J, Rhodes H, Paulus R, Murray K, Movsas B, Curran W: Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys; 2001 Sep 1;51(1):113-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.
  • PURPOSE: Fractionated external beam radiotherapy (EBRT) +/- carmustine (BCNU) is the standard of care for patients with glioblastoma multiforme (GBM), but survival results remain poor.
  • The Radiation Therapy Oncology Group (RTOG) therefore mounted a Phase II study to determine the feasibility and efficacy of conventional EBRT and concurrent weekly TAX at its MTD.
  • PATIENTS AND METHODS: Sixty-two patients with histologic diagnosis of GBM were enrolled from 8/16/96 through 3/21/97 in a multi-institutional Phase II trial of EBRT and TAX 225 mg/m(2)/3 h (1-3 h before EBRT), administered the first treatment day of each RT week.
  • Total EBRT dose was 60 Gy (200 cGy/fraction), 5 days per week.
  • A smaller treatment field, to include gross disease plus a margin only, was used after 46 Gy.
  • Recursive partitioning analysis (RPA) Classes III, IV, V, VI included 10 (17%), 21 (34%), 25 (41%), and 5 (8%) patients, respectively.
  • There was no Grade 3 or 4 neutropenia or thrombocytopenia.
  • There were 2 instances of late neurotoxicity (4% Grade 3 or 4).
  • Ninety-one percent of patients received treatment per protocol.
  • Seventy-seven percent completed prescribed treatment (6 weeks).
  • Median potential follow-up time is 20 months.
  • Median survival is 9.7 months, with median survivals for RPA classes III, IV, V, and VI of 16.3, 10.2, 9.5, 2.5 months, respectively.
  • Median survival by RPA class without prolonged adjuvant therapy is comparable to RTOG controls treated with standard EBRT and BCNU (1 year of BCNU).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Paclitaxel / administration & dosage. Radiation-Sensitizing Agents / administration & dosage. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11516860.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, Gilbert M, Newton HB, Hellman R, Eastern Cooperative Oncology Group: Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol; 2003 Apr 15;21(8):1485-91
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394.
  • PURPOSE: This phase III Eastern Cooperative Oncology Group-Southwest Oncology Group intergroup study was conducted to determine whether three 72-hour infusions of carmustine (BiCNU) and cisplatin administered monthly before external-beam radiotherapy would improve the survival of patients with newly diagnosed glioblastoma multiforme.
  • Treatment arms were well balanced with respect to baseline characteristics.
  • Median follow-up time of the 15 patients still alive at the time of analysis was 3.3 years (range, 2 to 5 years).
  • Median survival times for the standard and experimental arms were 11.2 and 11.0 months (P =.33, two-sided log-rank test), and survival at 1 year was 45% versus 44%, respectively.
  • CONCLUSION: This study demonstrates that 72-hour infusions of BiCNU and cisplatin followed by radiation do not improve median survival, survival at 1 year, or time to progression.
  • Furthermore, this treatment requires more time in the hospital and is associated with more serious toxicities than standard therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Carmustine / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Cisplatin / administration & dosage. Disease Progression. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Length of Stay. Male. Middle Aged. Odds Ratio. Radiotherapy, Adjuvant / adverse effects. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12697871.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04920; United States / NCI NIH HHS / CA / CA16116; United States / NCI NIH HHS / CA / CA21076; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / CA73590
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


11. Chamberlain MC: Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol; 2002 Jan;56(2):183-8
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme.
  • BACKGROUND: A prospective Phase II study of CPT-11 in adult patients with recurrent supratentorial glioblastoma multiforme (GBM).
  • All patients had previously been treated with surgery and involved field radiotherapy (median dose 60 Gy; range 59-60).
  • Additionally, all patients were treated with adjuvant chemotherapy (BCNU in 20, PCV in 18, Procarbazine in 2).
  • Recurrent disease was defined by neuroradiographic disease progression (>25% increase in tumor dimensions) using gadolinium-enhanced MR imaging.
  • No patient required transfusion nor was treatment for neutropenic fever required.
  • No treatment-related deaths were observed.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / therapeutic use. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy. Supratentorial Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2012 Feb;116(2):336-40; discussion 340 [22035270.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):860-4 [1849986.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1501-18 [11230497.001]
  • [Cites] Neurol Clin. 1985 Nov;3(4):831-42 [3908898.001]
  • [Cites] N Engl J Med. 1991 May 23;324(21):1471-6 [1822669.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3862-72 [11078500.001]
  • [Cites] N Engl J Med. 1991 May 30;324(22):1555-64 [2027359.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Jun;13(3):635-50, viii-ix [10432434.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurooncol. 1997 Sep;34(2):145-51 [9210061.001]
  • [Cites] J Clin Oncol. 1999 May;17 (5):1516-25 [10334539.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2585-97 [10914698.001]
  • [Cites] Surg Neurol. 1993 Jun;39(6):538-43 [8390727.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343 (13):905-14 [11006366.001]
  • [Cites] J Neurosurg. 1990 Apr;72 (4):583-8 [2319317.001]
  • [Cites] J Neurooncol. 1994;19(1):69-74 [7815106.001]
  • [Cites] Neurology. 1990 Nov;40(11):1743-6 [2172864.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1642-8 [7602353.001]
  • [Cites] Neurosurgery. 1994 Sep;35(3):378-88; discussion 388 [7800129.001]
  • [Cites] J Chronic Dis. 1961 Apr;13:346-53 [13704181.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • (PMID = 11995820.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Wolff JE, Mölenkamp G, Westphal S, Pietsch T, Gnekow A, Kortmann RD, Kuehl J: Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer; 2000 Nov 15;89(10):2131-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme.
  • BACKGROUND: Glioblastoma multiforme in childhood is rare, and the prognosis for patients with the disease is poor.
  • METHODS: Twenty-two patients with glioblastoma multiforme, World Health Organization Grade 4, between the ages of 3-15 years (45% male) were enrolled during the period 1995-1997.
  • There were 13 supratentorial tumors, 8 brainstem tumors, and 1 cerebellar tumor.
  • Adjuvant treatment consisted of oral chemotherapy with trofosfamide, 100 mg/m(2), and etoposide, 25 mg/m(2), daily or for 21-day cycles interrupted by 1-week rests.
  • RESULTS: The chemotherapy was well tolerated, with no treatment-related deaths and only minor side effects.
  • Two patients are alive after tumor progression: One patient was diagnosed with a medulloblastoma, and one patient was diagnosed with an osteosarcoma as second malignancies.
  • CONCLUSIONS: This chemotherapy will not be used in a randomized trial of patients with glioblastoma; however, it may be evaluated for patients with tumors that have more chemoresponsive histologies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Stem Neoplasms / drug therapy. Cyclophosphamide / therapeutic use. Etoposide / therapeutic use. Glioblastoma / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Child. Child, Preschool. Female. Humans. Male. Pilot Projects. Postoperative Care. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 11066055.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; H64JRU6GJ0 / trofosfamide
  •  go-up   go-down


13. Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS: Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg; 2004 Jan;100(1):41-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy.
  • OBJECT: For patients with recurrent glioblastomas multiforme (GBMs) the prognosis is poor.
  • Although chemotherapy may provide a survival advantage, the role of the extent of tumor resection, or the volume of the residual tumor at the time of recurrence, before instituting chemotherapy, is unclear.
  • This study was designed to assess the response to chemotherapy based on the volume of residual disease (VRD) at the start of treatment in patients with recurrent GBMs.
  • METHODS: One hundred nineteen adult patients with recurrent supratentorial GBMs received temozolomide chemotherapy at the time of tumor recurrence.
  • In this cohort the authors analyzed the prognostic significance of volumetrically assessed tumor mass on time to tumor progression (TTP) and survival time (ST).
  • Multivariate analysis demonstrated that the VRD at the beginning of chemotherapy was a statistically significant predictor of both TTP (p < 0.0001) and ST (p < 0.006) when adjusted for the patient's age, performance score, and time from the initial diagnosis.
  • Patients in whom the VRD was less than 10 cm3 at the start of chemotherapy had a 6-month progression-free survival rate of 32% compared with 8% for patients with a VRD between 10 and 15 cm3 and 3% for patients with a VRD larger than 15 cm3.
  • CONCLUSIONS: These data indicate that patients with recurrent GBMs who start chemotherapy with a smaller volume (< 10 cm3) of residual disease may have a more favorable response to chemotherapy and a more favorable outcome.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / pathology. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Predictive Value of Tests. Prognosis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14743910.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


14. Mangiola A, Maira G, De Bonis P, Porso M, Pettorini B, Sabatino G, Anile C: Glioblastoma multiforme in the elderly: a therapeutic challenge. J Neurooncol; 2006 Jan;76(2):159-63
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme in the elderly: a therapeutic challenge.
  • INTRODUCTION: Elderly patients with glioblastoma multiforme (GBM) are frequently excluded from cancer therapy trials, treated suboptimally or not treated at all.
  • The goal of the present study was to evaluate the efficacy of different treatment options in terms of survival in an elderly population affected with GBM.
  • MATERIALS AND METHODS: About 34 Patients with primary supratentorial GBM aged 65 or higher were included in this study.
  • All patients underwent craniotomy and tumor mass resection.
  • After surgery they received radiation therapy, chemotherapy and radioimmunotherapy in different combinations.
  • Survival according to adjuvant therapy has been 21 months (radiotherapy, chemotherapy, radioimmunotheraphy), 18 months (radiotherapy, chemotherapy) and 7 months (radiotherapy) (P=0.0001).
  • [MeSH-major] Glioblastoma / therapy. Supratentorial Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures. Prognosis. Radioimmunotherapy. Survival. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1991 Aug;36(2):106-11 [1891754.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):261-7 [12356356.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(4):443-7 [10717518.001]
  • [Cites] Oncology (Williston Park). 1995 Mar;9(3):229-34; discussion 237-8, 243 [7669516.001]
  • [Cites] J Neurooncol. 1999 Jun;43(2):187-93 [10533732.001]
  • [Cites] Cancer J. 2003 Mar-Apr;9(2):113-25 [12784877.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):657-62 [12548608.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):62-6; discussion 66-7 [8121570.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):58-62 [14765388.001]
  • [Cites] J Neurooncol. 1990 Aug;9(1):41-5 [2170591.001]
  • [Cites] Neurology. 1996 Oct;47(4):901-5 [8857716.001]
  • [Cites] J Neurooncol. 1992 Feb;12(2):125-30 [1560257.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1634-42 [8635069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):981-7 [9869219.001]
  • [Cites] Neurology. 1995 May;45(5):929-33 [7746409.001]
  • [Cites] Neurosurgery. 2001 Dec;49(6):1288-97; discussion 1297-8 [11846927.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):45-60; discussion 60-1 [8121569.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):63-7 [14765389.001]
  • [Cites] Lancet. 1982 Apr 17;1(8277):885-7 [6122104.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):2067-75 [1941065.001]
  • [Cites] Cancer. 2004 May 15;100(10 ):2208-14 [15139066.001]
  • [Cites] J Neurooncol. 1997 Jul;33(3):201-4 [9195491.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):835-9 [8040031.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1175-81 [12816260.001]
  • [Cites] Surg Neurol. 2004 Sep;62(3):207-13; discussion 214-5 [15336860.001]
  • [Cites] Radiother Oncol. 1994 Nov;33(2):113-6 [7535939.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2004 Sep;48(3):220-8 [15499296.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):635-44 [15497116.001]
  • [Cites] J Neurooncol. 1999 May;42(3):215-26 [10433105.001]
  • [Cites] Oncology. 1998 Jan-Feb;55(1):1-6 [9428367.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • (PMID = 16132492.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Afra D, Sipos L, Vitanovics D: [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)]. Ideggyogy Sz; 2002 Jan 20;55(1-2):38-44
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
  • At the Hungarian National Institute of Neurosurgery 73 recurrent supratentorial malignant tumours were treated by chemotherapy during the last ten years.
  • Chemotherapy was applied after postoperative radiotherapy but in some cases following reoperation only.
  • Forty-three patients received BCNU-DBD (dibromodulcitol) treatment (23 anaplastic astrocytoma--AA, and 20 glioblastoma multiforme--GM): day 1.
  • This course was repeated every six weeks, altogether 2-8 times.
  • Treatment started with vincristine 1.5 mg/sq.m. i.v. (2.0 mg maximum), the next day CCNU 100 mg/sq.m. was given, followed by procarbazine 60 mg/sq.m. on days 8-22. and finished by the same dose of vincristine on day 30.
  • The course was repeated after one month, mostly six times.
  • Chemotherapy of supratentorial malignant glioma recurrences with nitroso-ureas and their combination proved to be efficacious.
  • It also seems, that in recurrent cases lower grade gliomas show better response rate than glioblastomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Glioblastoma / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Carmustine / administration & dosage. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Mitolactol / administration & dosage. Neoplasm Recurrence, Local. Procarbazine / administration & dosage. Radiotherapy, Adjuvant. Reoperation. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12122942.001).
  • [ISSN] 0019-1442
  • [Journal-full-title] Ideggyógyászati szemle
  • [ISO-abbreviation] Ideggyogy Sz
  • [Language] hun
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; LJ2P1SIK8Y / Mitolactol; U68WG3173Y / Carmustine
  •  go-up   go-down


16. Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP, Yung WK, Radiation Therapy Oncology Group: Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol Phys; 2006 Nov 1;66(3):818-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710.
  • PURPOSE: The aim of this study was to determine whether recombinant human interferon beta-1a (rhIFN-beta), when given after radiation therapy, improves survival in glioblastoma.
  • METHODS AND MATERIALS: After surgery, 109 patients with newly diagnosed supratentorial glioblastoma were enrolled and treated with radiation therapy (60 Gy).
  • A total of 55 patients remained stable after radiation and were treated with rhIFN-beta (6 MU/day i.m., 3 times/week).
  • Outcomes were compared with the Radiation Therapy Oncology Group glioma historical database.
  • RESULTS: RhIFN-beta was well tolerated, with 1 Grade 4 toxicity and 8 other patients experiencing Grade 3 toxicity.
  • Median survival time (MST) of the 55 rhIFN-beta-treated patients was 13.4 months.
  • MST for the 34 rhIFN-beta-treated in RPA Classes III and IV was 16.9 vs. 12.4 months for historical controls (hazard ratio [HR] = 1.27, 95% confidence interval [CI] = 0.89-1.81).
  • CONCLUSION: RhIFN-beta given after conventional radiation therapy was well tolerated, with a trend toward survival benefit in patients who remained stable after radiation therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Interferon Type I / therapeutic use
  • [MeSH-minor] Combined Modality Therapy / methods. Confidence Intervals. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Recombinant Proteins. Regression Analysis. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / mortality. Supratentorial Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16887285.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon Type I; 0 / Recombinant Proteins
  •  go-up   go-down


17. Robins HI, Won M, Schultz C, Choucair A, Brachman D, Demas W, Mehta M: A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021. J Clin Oncol; 2004 Jul 15;22(14_suppl):1529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021.
  • Pretreatment characteristics included: 52%<60 years of age; 39% had a Zubrod score of 0, 70% had minor or no neurological symptoms; 65% were RTOG -recursive partition analysis (RPA) class III & IV.
  • Notable toxicity included: Late radiation Grade (G) G3 =2; Thrombo-embolic disease G2=2, G3=8, G4=3, G5=1 for an incidence of 18.7%, (which is lower than expected, based on the literature for DVT in GBM patients not receiving TAM).
  • Median survival time (MST) was 9.7 months (M).
  • This result was compared (using 3 different statistical methodologies) to the historical GBM control database of 1443 drug / XRT treated patients RPA class III, IV, & V.
  • After controlling for RPA class IV, the MST was 11.3M, which compares to the historical RPA control of 11.2 M (p=0.38). CONCLUSIONS:.
  • 1) The results obtained do not exhibit a substantial advance over previous studies with various XRT/drug doublets including BCNU.
  • As TAM does not have significant overlapping toxicities with most other drugs, its testing in a combined modality approach with other medications may be justified in future clinical trails.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015424.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Hwang SL, Lin CL, Lee KS, Lieu AS, Kuo TH, Chang CZ, Yen CP, Lin CK, Loh JK, Huang TY, Howng SL: Factors influencing seizures in adult patients with supratentorial astrocytic tumors. Acta Neurochir (Wien); 2004 Jun;146(6):589-94: discussion 594
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing seizures in adult patients with supratentorial astrocytic tumors.
  • Despite this, the investigation of seizures in adults with astrocytic tumors remains a grey area.
  • The incidence and influencing factors of preoperative and postoperative seizures were evaluated in 101 patients of 45 years or older with supratentorial astrocytic tumors.
  • Seizures at presentation were significantly correlated with pathological grades of astrocytic tumors (p = 0.0318).
  • The risk of seizures at presentation was greatest in patients with well-differentiated astrocytomas as compared with anaplastic astrocytomas (Odds ratio = 4.364, p = 0.056) or glioblastomas multiforme (Odds ratio = 5.673, p = 0.007).
  • Thirteen (72%) of 18 patients with postoperative seizures were associated with tumor recurrence in 7 cases, hemorrhage in 3 cases and malignant progression in 3 cases.
  • There was no association of postoperative seizures with age, sex, location or site of the tumors, grades of tumors, type of preoperative seizures, duration of preoperative seizures, serum level of anticonvulsant drug, extent of surgery, postoperative radiation or chemotherapy.
  • Imaging examination of brain to exclude the possibilities of tumor recurrence or hemorrhage is warrantable in supratentorial astrocytoma patients with postoperative seizures.
  • [MeSH-major] Astrocytoma / surgery. Epilepsy / etiology. Glioblastoma / surgery. Postoperative Complications / etiology. Supratentorial Neoplasms / surgery

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Springer-Verlag
  • (PMID = 15168227.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


19. López-Aguilar E, Sepúlveda-Vildósola AC, Rivera-Márquez H, Cerecedo-Díaz F, Hernández-Contreras I, Ramón-García G, Diegopérez-Ramírez J, Santacruz-Castillo E: Preirradiation ifosfamide, carboplatin, and etoposide for the treatment of anaplastic astrocytomas and glioblastoma multiforme: a phase II study. Arch Med Res; 2000 Mar-Apr;31(2):186-90
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preirradiation ifosfamide, carboplatin, and etoposide for the treatment of anaplastic astrocytomas and glioblastoma multiforme: a phase II study.
  • Traditional treatment of anaplastic astrocytoma (AA) and glioblastoma multiforme (GM) consisting of surgery-radiotherapy-chemotherapy with nitrosoureas has resulted in a survival rate of 26% at 1 year.
  • Neoadjuvant chemotherapy has proven good results in the treatment of other solid tumors.
  • Chemotherapy with ifosfamide, carboplatin, and etoposide (ICE) permits synergism among the different drugs and sensitizes the tumor to radiotherapy.
  • Our objective was to evaluate the efficacy, security, and survival rate of postoperative chemotherapy with ICE in pediatric patients with AA or GM.
  • We evaluated 11 children with AA or GM who had received no prior treatment.
  • A magnetic resonance image (MRI) study of the tumor was made after surgery to evaluate residual tumor and routine laboratory analysis.
  • Chemotherapy with carboplatin, ifosfamide and etoposide was given every 3 weeks for four courses.
  • Each patient then received hyperfractionated radiotherapy and a final MRI was done at the end of the treatment.
  • Supratentorial and infratentorial tumors had a good response to chemotherapy.
  • AA was the tumor with the greatest reduction of residual tumor after treatment.
  • CONCLUSIONS: Postoperative chemotherapy with ICE reduces the tumor size and increases the survival rate of pediatric patients with malignant astrocytomas with minimal toxicity.
  • Brainstem responded poorly to treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Cranial Irradiation. Glioblastoma / drug therapy. Premedication. Radiotherapy, Adjuvant
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Life Tables. Male. Mesna / administration & dosage. Prospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10880725.001).
  • [ISSN] 0188-4409
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] MEXICO
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; ICE protocol 5
  •  go-up   go-down


20. Kleinberg L, Grossman SA, Carson K, Lesser G, O'Neill A, Pearlman J, Phillips P, Herman T, Gerber M: Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J Clin Oncol; 2002 Jul 15;20(14):3149-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.
  • PURPOSE: The objectives of this phase II study were to determine survival, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of 2,4-[[(3,5-dimethylanilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid (RSR13, efaproxiral) 100 mg/kg per day administered with standard cranial radiotherapy (RT) for the treatment of glioblastoma multiforme (GBM).
  • RSR13, a synthetic allosteric modifier of hemoglobin, is a radiation-enhancing agent that noncovalently binds to hemoglobin, reduces oxygen-binding affinity, and increases oxygen unloading to hypoxic tissue.
  • Patients received daily RSR13 100 mg/kg intravenously infused for 30 minutes immediately before cranial RT (60 Gy in 30 fractions).
  • Supplemental oxygen was given during RSR13 infusion and continued until after the RT treatment was completed.
  • Twenty-four percent of patients had greater than grade 2 toxicity, which was generally transient and self-limited.
  • [MeSH-major] Aniline Compounds / therapeutic use. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Propionates / therapeutic use. Radiation-Sensitizing Agents / therapeutic use. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Confidence Intervals. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12118029.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62475
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Propionates; 0 / Radiation-Sensitizing Agents; 131179-95-8 / efaproxiral
  •  go-up   go-down


21. Terasaki M, Ogo E, Fukushima S, Sakata K, Miyagi N, Abe T, Shigemori M: Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial. Surg Neurol; 2007 Sep;68(3):250-4
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial.
  • We examined the case histories of these 7 patients and determined the location of tumor and extent of their surgical procedures.
  • We calculated survival times from time of initial surgery and compared actual survival with statistically predicted survival times for each patient.
  • RESULTS: Median survival rates were higher than predicted: The statistical risk estimate for median survival time after repeat surgery for these patients was 9 months; the actual survival time from initial operation until time of death averaged 15.1 months.
  • Survival time did not depend on removing the entire tumor at initial and second surgery.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / surgery. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Cohort Studies. Feasibility Studies. Female. Humans. Male. Middle Aged. Reoperation. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17719957.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


22. Classen CF, Warmuth-Metz M, Papke K, Trotter A, Wolff JE, Wagner S: Late response to radiochemotherapy in pediatric glioblastoma: report on two patients treated according to HIT-GBM protocols. Pediatr Hematol Oncol; 2006 Dec;23(8):631-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late response to radiochemotherapy in pediatric glioblastoma: report on two patients treated according to HIT-GBM protocols.
  • High-grade gliomas in children are rare and the best treatment is undetermined.
  • Imaging is done 3 weeks after to define treatment response, followed by 6-weekly controls during consolidation with lomustine, vincristine, and prednisone.
  • The authors report on 2 patients with incompletely resected glioblastoma multiforme in which response was lacking 3 weeks after radiochemotherapy but became evident 12 weeks later.
  • This suggests that later time points are required to assess induction protocol response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / radiotherapy. Cranial Irradiation. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Child. Cisplatin / administration & dosage. Combined Modality Therapy. Craniotomy. Disease Progression. Etoposide / administration & dosage. Fatal Outcome. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Male. Randomized Controlled Trials as Topic. Remission Induction. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065139.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


23. Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, Cloughesy T, Lamborn KR, Salazar AM, Prados MD: A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol; 2009 Jan;91(2):175-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).
  • PURPOSE: This phase II study was designed to determine the overall survival time of adults with supratentorial glioblastoma treated with the immune modulator, polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), in combination with and following radiation therapy (RT).
  • Poly-ICLC was initiated 7-28 days after the surgical procedure that established the diagnosis; radiotherapy began within 7 days of the first dose of poly-ICLC and within 35 days of surgical diagnosis.
  • Treatment with poly-ICLC continued following the completion of RT to a maximum of 1 year or until tumor progression.
  • One patient did not have a Glioblastoma mutiforme and was deemed ineligible.
  • For the 30 eligible patients, time to progression was known for 27 patients and 3 were censored.
  • Median time to progression was as 18 weeks.
  • CONCLUSIONS: The combined therapy was relatively well-tolerated.
  • This study suggests a survival advantage compared to historical studies using RT without chemotherapy but no survival advantage compared to RT with adjuvant nitrosourea or non-temozolomide chemotherapy.
  • Our results suggest that poly-ICLC has activity against glioblastoma and may be worth further study in combination with agents such as temozolomide.
  • [MeSH-major] Carboxymethylcellulose Sodium / analogs & derivatives. Glioblastoma / therapy. Interferon Inducers / therapeutic use. Poly I-C / therapeutic use. Polylysine / analogs & derivatives. Radiotherapy / methods. Supratentorial Neoplasms / therapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797818.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062399
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Interferon Inducers; 24939-03-5 / Poly I-C; 25104-18-1 / Polylysine; 59789-29-6 / poly ICLC; 9004-32-4 / Carboxymethylcellulose Sodium
  • [Other-IDs] NLM/ NIHMS761679; NLM/ PMC4779120
  •  go-up   go-down


24. Everaert E, Neyns B, Joosens E, Strauven T, Branle F, Menten J: Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. J Neurooncol; 2004 Oct;70(1):37-48
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
  • Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent high-grade gliomas in prospective phase II studies.
  • We conducted a retrospective study to evaluate the activity and safety of TMZ that was prescribed for the treatment of recurrent glioma in the context of a compassionate use program in Belgium.
  • Data were obtained on 117 adult patients (from five hospitals) who received TMZ as first or second line chemotherapy.
  • Thrombocytopenia was the most frequent treatment related adverse event (grade 3/4 in 17% of patients).
  • In multivariate analysis a 'deep localization' of the glioma (as opposed to a cortico-subcortical localization) and 'the preceding history of a low-grade glioma' were respectively identified as a negative and positive independent prognostic variable for survival.
  • No significant difference in terms of response or median survival was observed between patients with anaplastic astrocytoma or oligo-astrocytoma and chemonaive glioblastoma multiforme.
  • This retrospective study indicates that the reported activity and toxicity profile of TMZ for the treatment of patients with recurrent glioma is reproducible outside the setting of a prospective clinical trial.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Belgium. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):128-38 [12672285.001]
  • [Cites] Stat Med. 1984 Jan-Mar;3(1):35-44 [6729287.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):261-7 [12356356.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Ann Oncol. 2003 Dec;14 (12 ):1722-6 [14630675.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):482-90 [8595163.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2236-41 [9038604.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Med Oncol. 2000 May;17 (2):106-10 [10871815.001]
  • [Cites] Neurology. 1998 Oct;51(4):1140-5 [9781544.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(6):484-8 [9332462.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;26(6):429-36 [2225314.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] J Neurooncol. 2002 May;57(3):247-51 [12125988.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):14-25 [11554386.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):605-11 [14745879.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] Neurosurgery. 1998 Nov;43(5):1066-73 [9802850.001]
  • [Cites] Ann Oncol. 2003 Dec;14 (12 ):1715-21 [14630674.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Br J Cancer. 1999 Nov;81(6):1022-30 [10576660.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):255-7 [11300334.001]
  • [Cites] Drugs R D. 2003;4(5):285-91 [12952497.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • (PMID = 15527106.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


25. Fujii O, Soejima T, Kuwatsuka Y, Harada A, Ota Y, Tsujino K, Sasaki M, Kudo H, Nishihara M, Taomoto K: Supratentorial glioblastoma treated with radiotherapy: use of the Radiation Therapy Oncology Group recursive partitioning analysis grouping for predicting survival. Jpn J Clin Oncol; 2010 Aug;40(8):726-31
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial glioblastoma treated with radiotherapy: use of the Radiation Therapy Oncology Group recursive partitioning analysis grouping for predicting survival.
  • OBJECTIVE: This study aimed to evaluate the usefulness of recursive partitioning analysis model established by the Radiation Therapy Oncology Group for predicting the survival of patients with supratentorial glioblastoma treated with radiotherapy and to determine prognostic factors for the subgroups of this prognostic model.
  • METHODS: A total of 108 glioblastoma patients treated with radiotherapy between January 1987 and December 2005 were retrospectively reviewed.
  • Recursive partitioning analysis classes III, IV, V and VI included 8, 29, 32 and 39 patients, respectively.
  • These classes were divided into two subgroups: a good prognostic group containing classes III-IV and a poor prognostic group containing classes V-VI.
  • The median radiation dose was 60 Gy.
  • Seventy-five patients received chemotherapy and/or immunotherapy.
  • RESULTS: The overall survival differed significantly among classes III, IV, V and VI, with median survival times of 34, 15, 11 and 7 months, respectively.
  • Among the poor prognostic group, patients with tumor sizes of <5 cm and patients treated with nimustine hydrochloride showed better survival outcomes than those with tumor sizes of > or =5 cm and those without treatment with nimustine hydrochloride, respectively.
  • Basal ganglia invasion could be a useful predictive factor for survival in the good prognostic group, whereas tumor size and treatment with nimustine hydrochloride could be useful predictive factors in the poor prognostic group.
  • [MeSH-major] Glioblastoma / mortality. Glioblastoma / radiotherapy. Models, Statistical. Supratentorial Neoplasms / mortality. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Immunotherapy. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20410057.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Durando X, Lemaire JJ, Tortochaux J, Van-Praagh I, Kwiatkowski F, Vincent C, Bailly C, Verrelle P, Irthum B, Chazal J, Bay JO: High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone Marrow Transplant; 2003 Apr;31(7):559-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
  • Conventional treatment of high-grade glioma includes maximal surgical resection followed by external radiation therapy.
  • Despite this treatment, the prognosis for patients is poor.
  • High doses of chemotherapy might be another way to increase the response rate and median survival.
  • We report our experience of high-dose BCNU followed by transplantation of autologous hematopoietic stem cells in 114 patients with high-grade gliomas.
  • Of the 114 gliomas, 78 were glioblastoma multiforme (GM) (68%), 24 anaplastic astrocytomas (AA) (21%), and 12 anaplastic oligodendrogliomas (OD) (11%).
  • Bone marrow or PBPC was transplanted 48-72 h after chemotherapy.
  • Radiotherapy was started approximately 40 days after transplantation to a total of 60 Gy.
  • Histological type appeared to be the main discriminating factor, with a worse prognosis for GM.
  • On multivariate analysis, the main prognostic factors were histologic type, quality of surgery, and age (P<0.005).
  • Five of 114 patients had lethal complications from the procedure.
  • We observed long-term survivors, although the OS and the time to treatment failure seem to be comparable to that described for other treatment.
  • Additional pilot studies are unlikely to reveal more than a modest benefit from this procedure and therefore a randomized study should be performed.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Carmustine / administration & dosage. Glioblastoma / drug therapy. Hematopoietic Stem Cell Transplantation. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / surgery. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Oligodendroglioma / drug therapy. Oligodendroglioma / mortality. Oligodendroglioma / surgery. Prognosis. Retrospective Studies. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12692621.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; U68WG3173Y / Carmustine
  •  go-up   go-down


27. Butowski N, Prados MD, Lamborn KR, Larson DA, Sneed PK, Wara WM, Malec M, Rabbitt J, Page M, Chang SM: A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys; 2005 Apr 1;61(5):1454-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.
  • PURPOSE: This Phase II study was designed to determine the median survival time of adults with supratentorial glioblastoma treated with a combination of temozolomide (TMZ) and 13-cis-retinoic acid (cRA) given daily with conventional radiation therapy (XRT).
  • Both drugs were administered starting on Day 1 of XRT, and chemotherapy cycles continued after the completion of XRT to a maximum of 1 year.
  • Time to progression was known for 55 patients and 6 were censored.
  • Median time to progression was estimated as 21 weeks.
  • CONCLUSIONS: The combined therapy was relatively well tolerated, but there was no survival advantage compared with historical studies using XRT either with adjuvant nitrosourea chemotherapy, with TMZ alone, or with the combination of TMZ and thalidomide.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Isotretinoin / administration & dosage. Male. Middle Aged. Proportional Hazards Models

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15817350.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EH28UP18IF / Isotretinoin
  •  go-up   go-down


28. Yamasaki F, Sugiyama K, Ohtaki M, Takeshima Y, Abe N, Akiyama Y, Takaba J, Amatya VJ, Saito T, Kajiwara Y, Hanaya R, Kurisu K: Glioblastoma treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging. Eur J Radiol; 2010 Mar;73(3):532-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging.
  • PURPOSE: To retrospectively evaluate whether the mean, minimum, and maximum apparent diffusion coefficient (ADC) of glioblastomas obtained from pretreatment MR images is of prognostic value in patients with glioblastoma.
  • Between February 1998 and January 2006, 33 patients (24 males, 9 females; age range 10-76 years) with supratentorial glioblastoma underwent pretreatment magnetic resonance (MR) imaging.
  • The values of the mean, minimum, and maximum ADC (ADC(mean), ADC(MIN), and ADC(MAX), respectively) of each tumor were preoperatively determined from several regions of interest defined in the tumors.
  • After surgical intervention, all patients underwent irradiation and chemotherapy performed according to our hospital protocol.
  • Interestingly, ADC(MIN) was also the strongest prognostic factor (P<0.01) in the group of patients in whom total tumor removal was not possible.
  • CONCLUSION: The ADC(MIN) value obtained from pretreatment MR images is a useful clinical prognostic biomarker in patients with glioblastoma.
  • [MeSH-major] Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Magnetic Resonance Imaging / methods. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / radiography
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Contrast Media. Female. Humans. Image Interpretation, Computer-Assisted. Male. Middle Aged. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19250783.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


29. Kumagai T, Takeda N, Fukase S, Koshu H, Inoue A, Ibuchi Y, Yoneoka Y: Intra-arterial Chemotherapy for Malignant Tumors of Head and Neck Region Using Three Types of Modified Injection Method. Interv Neuroradiol; 2003 May 15;9(Suppl 1):113-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial Chemotherapy for Malignant Tumors of Head and Neck Region Using Three Types of Modified Injection Method.
  • SUMMARY: Relatively higher infusion rate in the intra-arterial chemotherapy (IA chemotherapy) could induce the higher concentration and the more sufficient distribution of chemotherapeutic agents on tumors.
  • To get the relatively higher infusion rate in IA chemotherapy, we used three types of injection method: high-flow injection, high-dose injection with detoxification and flowcontrolled injection method for the treatment of malignant brain tumors, skull base tumors and head and neck tumors.
  • Between January 1997 and October 2001, twenty-seven patients (mean age 61 y.o.) with supratentorial glioblastoma (4 cases), supratentorial anaplastic astrocytoma (1), CNS lymphoma (2), matastatic skull base tumors (3), and neck tumors (15 squamous cell carcinoma, 1 malignant melanoma and 1 neuroblastoma) received our three types of IA chemotherapy.
  • Conventional radiation therapy and/or surgical removal were performed in some of these patients.
  • Fifteen (55.6%) and 6 (22.2%) of 27 patients achieved complete response (CR) and partial response (PR) respectively after initial treatment [CR+PR: 21 (77.8%)].
  • The median post treatment survival was 12 months.
  • Our modified IA chemotherapy has provided favorable clinical and radiological results without technical difficulties and serious complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1999 Oct;213(1):135-40 [10540653.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):637-47 [10649259.001]
  • [Cites] Cancer. 2000 May 15;88(10):2350-6 [10820358.001]
  • [Cites] J Neurooncol. 2000 Aug;49(1):63-70 [11131988.001]
  • [Cites] J Neurosurg. 1992 May;76(5):772-81 [1564540.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):79-86 [8455066.001]
  • [Cites] Radiology. 1993 Aug;188(2):347-50 [8327676.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):263-71 [9226312.001]
  • [Cites] Biol Pharm Bull. 1999 Apr;22(4):428-31 [10328568.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):235-46 [10359143.001]
  • [Cites] J Neurooncol. 1999 Mar;42(1):73-7 [10360481.001]
  • [Cites] Microcirculation. 2000 Dec;7(6 Pt 1):405-10 [11142337.001]
  • [Cites] Radiology. 2001 Mar;218(3):724-32 [11230646.001]
  • [Cites] Am J Clin Oncol. 2001 Jun;24(3):241-6 [11404493.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1079-85, viii [11728933.001]
  • [Cites] Head Neck. 2002 Jan;24(1):68-77 [11774405.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1476-82 [11920504.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1989 Mar;41(3):293-300 [2471758.001]
  • [Cites] J Neurosurg. 1991 May;74(5):763-72 [1849555.001]
  • (PMID = 20591239.001).
  • [ISSN] 1591-0199
  • [Journal-full-title] Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
  • [ISO-abbreviation] Interv Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3553465
  •  go-up   go-down


30. Jennings MT, Cmelak A, Johnson MD, Moots PL, Pais R, Shyr Y: Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy. Pediatr Blood Cancer; 2004 Jul;43(1):46-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy.
  • BACKGROUND: These factors have been predictive for progressive disease on therapy (PDOT) among pediatric brain tumors: >1.5 cm(2) unresectable tumor, glioblastoma, supratentorial primitive neuroectodermal tumor, and metastatic medulloblastoma (MBL).
  • Maintenance chemotherapy consisted of eight cycles of carboplatin, etoposide, and vincristine.
  • Induction chemotherapy produced partial and minor responses (MRs) among 5/10.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Dose Fractionation. Etoposide / administration & dosage. Female. Humans. Male. Neoadjuvant Therapy. Pilot Projects. Statistics, Nonparametric. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15170889.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Cummings TJ, Hulette CM, Bigner SH, Riggins GJ, McLendon RE: Ham56-immunoreactive macrophages in untreated infiltrating gliomas. Arch Pathol Lab Med; 2001 May;125(5):637-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To identify macrophages in untreated, infiltrating gliomas using the monoclonal antibody HAM56, and to confirm their presence in an untreated glioblastoma multiforme (GBM) with the serial analysis of gene expression (SAGE) method.
  • METHODS: We evaluated the presence of macrophages in 16 cases of untreated, supratentorial infiltrating gliomas with the macrophage monoclonal antibody HAM56.
  • We performed SAGE for one case of GBM and for normal brain tissue.
  • RESULTS: In World Health Organization (WHO) grade II well-differentiated astrocytoma and oligodendroglioma, HAM56 reactivity was noted only in endothelial cells, and unequivocal macrophages were not identified.
  • In WHO grade III anaplastic astrocytoma and anaplastic oligodendroglioma, rare HAM56-positive macrophages were noted in solid areas of tumor.
  • In WHO grade IV GBM, HAM56-positive macrophages were identified in areas of solid tumor (mean labeling index, 8.6%).
  • In none of the cases were granulomas or microglial nodules found, and there was no prior history of surgical intervention, radiation therapy, chemotherapy, or head trauma in these cases.
  • By SAGE, the macrophage-related proteins osteopontin and macrophage-capping protein were overexpressed 12-fold and eightfold, respectively, in one untreated GBM compared with normal brain tissue.
  • In this case, numerous HAM56-positive macrophages (labeling index, 24.5%) were present in the solid portion of tumor, and abundant nonquantified macrophages were identified in foci of pseudopalisading cells abutting necrosis and in foci of microvascular proliferations.
  • [MeSH-minor] Adult. Aged. Biomarkers / analysis. Female. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / biosynthesis. Supratentorial Neoplasms / genetics. Supratentorial Neoplasms / metabolism. Supratentorial Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11300934.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers; 0 / HAM-56 antibody; 0 / RNA, Messenger
  •  go-up   go-down


32. Weber FW, Floeth F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Rommell F, Pan H, Hingorani VN, Puri RK: Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl; 2003;88:93-103
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma.
  • PATIENTS AND METHODS: A total of 31 patients with histologically verified supratentorial grade 3 and 4 astrocytoma were studied.
  • Of these, twenty-five patients were diagnosed with glioblastoma multiforme (GBM) while six were diagnosed with anaplastic astrocytoma (AA).
  • RESULTS: No drug-related systemic toxicity, as evident by lack of hematological or serum chemical changes, was apparent in any patients; treatment-related adverse effects were limited to the central nervous system.
  • No deaths were attributable to treatment.
  • Drug-related Grade 3 or 4 toxicity was seen in 39% of patients in all dose groups and 22% of patients at the maximum tolerated dose of 6 microg/ml x 40 ml.
  • Gadolinium-enhanced magnetic resonance imaging of the brain showed areas of decreased signal intensity within the tumor consistent with tumor necrosis following treatment in many patients.
  • [MeSH-major] Astrocytoma / drug therapy. Bacterial Toxins / administration & dosage. Exotoxins / administration & dosage. Glioblastoma / drug therapy. Immunotoxins / administration & dosage. Interleukin-4 / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intralesional. Magnetic Resonance Imaging. Male. Middle Aged. Prospective Studies. Stereotaxic Techniques

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14531567.001).
  • [ISSN] 0065-1419
  • [Journal-full-title] Acta neurochirurgica. Supplement
  • [ISO-abbreviation] Acta Neurochir. Suppl.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Bacterial Toxins; 0 / Exotoxins; 0 / Immunotoxins; 0 / interleukin-4-Pseudomonas exotoxin; 207137-56-2 / Interleukin-4
  •  go-up   go-down


33. Kochii M, Kitamura I, Goto T, Nishi T, Takeshima H, Saito Y, Yamamoto K, Kimura T, Kino T, Tada K, Shiraishi S, Uemura S, Iwasaki T, Kuratsu J, Ushio Y: Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma. J Neurooncol; 2000 Aug;49(1):63-70
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma.
  • This prospective randomized trial was performed to compare the effectiveness of intra-arterial ACNU with intravenous ACNU in newly diagnosed patients with supratentorial glioblastoma.
  • Patients characteristics were not different significantly between 2 treatment arms.
  • Median survival and progression-free survival time was 59 and 24 weeks, respectively for intra-arterial arm and 56 and 45 weeks, respectively for intravenous arm.
  • There was no significant difference respectively between two treatment arms.
  • Among the prognostic variables including age, Karnofsky performance status, extent of surgery and treatment arm, Cox's proportional hazards model showed that age was the only significant factor for both survival and progression-free survival (P = 0.003 and 0.016, respectively).
  • With regard to toxicity, there was no significant difference between two treatment arms.
  • In conclusion, intra-arterial ACNU when administered by the method in this study does not increase the survival and progression-free survival of newly diagnosed patients with glioblastoma over that afforded by intravenous ACNU.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Nimustine / administration & dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1988;21(3):185-90 [3129204.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Cancer Treat Rep. 1983 Feb;67(2):121-32 [6337710.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2123-8 [3470138.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):1984-94 [2553234.001]
  • [Cites] J Neurosurg. 1984 Sep;61(3):423-9 [6747681.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):131-5 [1331343.001]
  • [Cites] J Neurooncol. 1995;23(3):223-31 [7673984.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Neurosurg. 1992 May;76(5):772-81 [1564540.001]
  • [Cites] J Neurooncol. 1986;3(4):297-314 [3958776.001]
  • [Cites] J Neurosurg. 1986 Jan;64(1):53-7 [3455717.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):876-80 [2997415.001]
  • [Cites] Natl Cancer Inst Monogr. 1977 Dec;46:19-27 [349396.001]
  • [Cites] J Neurosurg. 1978 Apr;48(4):587-93 [416182.001]
  • [Cites] J Neurooncol. 1989 Sep;7(3):269-81 [2795121.001]
  • [Cites] J Neurosurg. 1983 Jul;59(1):106-10 [6306179.001]
  • [Cites] Neurology. 1994 Aug;44(8):1479-83 [8058153.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):141-7 [8699236.001]
  • [Cites] J Neurosurg. 1991 May;74(5):763-72 [1849555.001]
  • [Cites] Cancer Treat Rep. 1977 Jul;61(4):519-26 [884689.001]
  • (PMID = 11131988.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0S726V972K / Nimustine
  •  go-up   go-down


34. Massimino M, Gandola L, Luksch R, Spreafico F, Riva D, Solero C, Giangaspero F, Locatelli F, Podda M, Bozzi F, Pignoli E, Collini P, Cefalo G, Zecca M, Casanova M, Ferrari A, Terenziani M, Meazza C, Polastri D, Scaramuzza D, Ravagnani F, Fossati-Bellani F: Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol; 2005 Jan;7(1):41-8
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma.
  • Childhood malignant gliomas are rare, but their clinical behavior is almost as aggressive as in adults, with resistance to therapy, rapid progression, and not uncommonly, dissemination.
  • Our study protocol incorporated sequential chemotherapy and high-dose thiotepa in the preradiant phase, followed by focal radiotherapy and maintenance with vincristine and lomustine for a total duration of one year.
  • The induction treatment consisted of two courses of cisplatin (30 mg/m2) plus etoposide (150 mg/m2) x 3 days and of vincristine (1.4 mg/m2) plus cyclophosphamide (1.5 g/m2) plus high-dose methotrexate (8 g/m2), followed by high-dose thiotepa (300 mg/m2 x 3 doses), with harvesting of peripheral blood progenitor cells after the first cisplatin/etoposide course.
  • Histologies were glioblastoma multiforme in 10, anaplastic astrocytoma in nine, and anaplastic oligodendroglioma in two; sites of origin were supratentorial areas in 17, spine in two, and posterior fossa in two.
  • Of the 21 patients, 12 have died (10 after relapse, with a median time to progression for the whole series of 14 months; one with intratumoral bleeding at 40 months after diagnosis; and one affected by Turcot syndrome for duodenal cancer relapse).
  • Four of 12 relapsed children had tumor dissemination.
  • Sequential and high-dose chemotherapy can be afforded in front-line therapy of childhood malignant glioma without excessive morbidity and rather encouraging results.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Glioma / therapy. Thiotepa / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Blood Component Transfusion. Child. Child, Preschool. Combined Modality Therapy. Erythroid Precursor Cells. Female. Humans. Male. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S1-5 [8971398.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(1):72-4 [9137533.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3C):2073-7 [9216666.001]
  • [Cites] Ann Genet. 1997;40(2):78-91 [9259954.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):553-9 [9324343.001]
  • [Cites] Med Pediatr Oncol. 1998 Feb;30(2):75-80 [9403013.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):210-21 [9440745.001]
  • [Cites] Childs Nerv Syst. 1997 Nov-Dec;13(11-12):572-7 [9454971.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 15;90(8):606-11 [9554443.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2486-93 [9667268.001]
  • [Cites] Klin Padiatr. 1998 Jul-Aug;210(4):227-33 [9743957.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(7):661-7 [9818693.001]
  • [Cites] Med Pediatr Oncol. 1998 Dec;31(6):483-90 [9835900.001]
  • [Cites] Med Pediatr Oncol. 1999 Aug;33(2):83-7 [10398181.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2117-23 [10570440.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):786-8 [10603023.001]
  • [Cites] Med Pediatr Oncol. 2000 Feb;34(2):147-50 [10657880.001]
  • [Cites] Childs Nerv Syst. 2000 Jan;16(1):15-20 [10672424.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(2):153-60 [10918425.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):815-9 [11937316.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3569-72 [12552957.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):416-20 [3574617.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):736-41 [2491958.001]
  • [Cites] J Neurooncol. 1989 May;7(1):5-11 [2754456.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):583-8 [2319317.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2771-8 [2160318.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):227-33 [1534708.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):112-8 [8478137.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1458-65 [8336185.001]
  • [Cites] Med Pediatr Oncol. 1994;23(5):428-36 [8084310.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Eur J Cancer. 1997 Jan;33(1):91-5 [9071906.001]
  • (PMID = 15701281.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 905Z5W3GKH / Thiotepa
  • [Other-IDs] NLM/ PMC1871624
  •  go-up   go-down


35. Joensuu H, Kankaanranta L, Seppälä T, Auterinen I, Kallio M, Kulvik M, Laakso J, Vähätalo J, Kortesniemi M, Kotiluoto P, Serén T, Karila J, Brander A, Järviluoma E, Ryynänen P, Paetau A, Ruokonen I, Minn H, Tenhunen M, Jääskeläinen J, Färkkilä M, Savolainen S: Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine. J Neurooncol; 2003 Mar-Apr;62(1-2):123-34
Hazardous Substances Data Bank. BORON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine.
  • Two clinical trials are currently running at the Finnish dedicated boron neutron capture therapy (BNCT) facility.
  • Between May 1999 and December 2001, 18 patients with supratentorial glioblastoma were treated with boronophenylalanine (BPA)-based BNCT within a context of a prospective clinical trial (protocol P-01).
  • All patients underwent prior surgery, but none had received conventional radiotherapy or cancer chemotherapy before BNCT.
  • The average planning target volume dose ranged from 30 to 61 Gy (W), and the average normal brain dose from 3 to 6 Gy (W).
  • The treatment was generally well tolerated, and none of the patients have died during the first months following BNCT.
  • In another trial (protocol P-03), three patients with recurring or progressing glioblastoma following surgery and conventional cranial radiotherapy to 50-60 Gy, were treated with BPA-based BNCT using the BPA dosage of 290 mg/kg.
  • The average planning target dose in these patients was 25-29 Gy (W), and the average whole brain dose 2-3 Gy (W).
  • We conclude that BPA-based BNCT has been relatively well tolerated both in previously irradiated and unirradiated glioblastoma patients.
  • Efficacy comparisons with conventional photon radiation are difficult due to patient selection and confounding factors such as other treatments given, but the results support continuation of clinical research on BPA-based BNCT.
  • [MeSH-major] Boron Compounds / therapeutic use. Boron Neutron Capture Therapy. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Boron / blood. Dose-Response Relationship, Radiation. Female. Finland. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Prospective Studies. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Res. 1999 Jan;151(1):1-18 [9973079.001]
  • [Cites] J Comput Assist Tomogr. 1980 Aug;4(4):489-91 [6771308.001]
  • [Cites] J Neurooncol. 2001 Apr;52(2):101-10 [11508809.001]
  • [Cites] Neurosurgery. 2000 Jul;47(1):189-97; discussion 197-8 [10917362.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8179-87 [11719448.001]
  • [Cites] Med Phys. 1999 Jul;26(7):1237-44 [10435523.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):127-37 [11325440.001]
  • [Cites] Radiother Oncol. 1998 Sep;48(3):313-7 [9925251.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):829-34 [9531367.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1145-54 [11072174.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):459-64 [8436524.001]
  • [Cites] Phys Med Biol. 2002 Mar 7;47(5):737-45 [11931468.001]
  • [Cites] J Nucl Med. 1997 Nov;38(11):1762-7 [9374349.001]
  • [Cites] J Nucl Med. 1998 Feb;39(2):325-33 [9476945.001]
  • [Cites] Clin Chem. 2001 Oct;47(10):1796-803 [11568089.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Neurosurgery. 1999 Jun;44(6):1182-92; discussion 1192-3 [10371617.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1825-32 [9717808.001]
  • [Cites] Ann Med. 2000 Feb;32(1):81-5 [10711581.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Med Phys. 1999 Jul;26(7):1230-6 [10435522.001]
  • (PMID = 12749708.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boron Compounds; N9E3X5056Q / Boron
  •  go-up   go-down


36. Ducray F, Colin P, Cartalat-Carel S, Pelissou-Guyotat I, Mahla K, Audra P, Gaucherand P, Honnorat J, Trouillas P: [Management of malignant gliomas diagnosed during pregnancy]. Rev Neurol (Paris); 2006 Mar;162(3):322-9
Hazardous Substances Data Bank. Fotemustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Prise en charge des gliomes malins découverts au cours d'une grossesse.
  • In post-partum additional treatment with chemotherapy was started.
  • Histology revealed a glioblastoma multiforme.
  • In post-partum additional treatment with radiotherapy and chemotherapy was started.
  • Histology revealed a glioblastoma multiforme.
  • Two weeks after surgery the patient's neurological condition worsened and in agreement with the patient a therapeutic abortion was decided.
  • Afterwards additional treatment with radiotherapy and chemotherapy was started.
  • The last patient received combined treatment with radiotherapy and chemotherapy for local recurrence of a mesencephalic high-grade glioma.
  • A posteriori it was discovered that the patient was at 4 months' gestation during this treatment.
  • Their pregnancy should not prevent them from receiving the best treatment for their glioma.
  • Treatment will depend upon clinico-radiological presentation, histology, gestational age and the patient's desires.
  • Generally speaking, surgical resection of high-grade gliomas should not be delayed during pregnancy.
  • After the first trimester of gestation this treatment can be given without any important risks for the child.
  • [MeSH-major] Case Management. Glioblastoma / therapy. Pregnancy Complications, Neoplastic / therapy. Supratentorial Neoplasms / therapy
  • [MeSH-minor] Abortion, Therapeutic. Adrenal Cortex Hormones / therapeutic use. Adult. Algorithms. Anesthesia, General. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carbamazepine / therapeutic use. Carmustine / administration & dosage. Cesarean Section. Chemotherapy, Adjuvant. Cranial Irradiation. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Frontal Lobe. Humans. Infant, Newborn. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Nitrosourea Compounds / administration & dosage. Nitrosourea Compounds / therapeutic use. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / therapeutic use. Paresis / drug therapy. Paresis / etiology. Prednisolone / therapeutic use. Pregnancy. Prenatal Exposure Delayed Effects. Radiotherapy, Adjuvant. Remission Induction. Temporal Lobe

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Neurol (Paris). 2006 Mar;162(3):293-4 [16585883.001]
  • (PMID = 16585887.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 33CM23913M / Carbamazepine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9PHQ9Y1OLM / Prednisolone; GQ7JL9P5I2 / fotemustine; U68WG3173Y / Carmustine
  •  go-up   go-down


37. Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M, North American Brain Tumor Consortium: Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol; 2003 Jun 15;21(12):2305-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
  • This phase II trial evaluated efficacy and toxicity of combination temozolomide and cRA treatment in recurrent MG.
  • PATIENTS AND METHODS: Adults with recurrent supratentorial MG for whom surgery, radiation, and/or chemotherapy failed were eligible.
  • Treatment included oral TMZ 150 or 200 mg/m2/d, days 1 through 5, and cRA 100 mg/m2/d, days 1 to 21, every 28 days.
  • RESULTS: Eighty-eight eligible patients (glioblastoma multiforme [n = 40]; anaplastic gliomas [n = 48; astrocytoma, 28; oligodendroglioma, 14; mixed glioma, six]) received treatment.
  • Among 499 treatment cycles, the most common grade 3/4 events included granulocytopenia (1.8%), thrombocytopenia (1.4%), and hypertriglyceridemia (1.2%).
  • CONCLUSION: TMZ and cRA were active, exceeding our 20% thresholds for PFS 6 success, assuming 20% improvement over our previously reported database (glioblastoma multiforme: expected, 30%; observed, 32%; anaplastic glioma: expected, 40%; observed, 50%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / analogs & derivatives. Glioma / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Disease Progression. Female. Humans. Isotretinoin / administration & dosage. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12805331.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / CA62426; United States / NCI NIH HHS / CA / CA62455; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00633; United States / NCRR NIH HHS / RR / M01-RR03186; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCRR NIH HHS / RR / MO1-RR00056; United States / NCI NIH HHS / CA / UO1CA62399; United States / NCI NIH HHS / CA / UO1CA62405; United States / NCI NIH HHS / CA / UO1CA62407-08; United States / NCI NIH HHS / CA / UO1CA62421
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EH28UP18IF / Isotretinoin
  •  go-up   go-down


38. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y: Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery; 2004 Feb;54(2):349-57; discussion 357
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy.
  • We investigated whether MGMT promoter hypermethylation is associated with prognosis in patients with high-grade astrocytic tumors treated uniformly with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU)-based chemotherapy.
  • METHODS: Using the methylation-specific polymerase chain reaction, we assayed promoter hypermethylation of the MGMT gene in tumor deoxyribonucleic acid from 116 adult patients with supratentorial high-grade astrocytic tumors (42 anaplastic astrocytomas [AAs] and 74 glioblastomas multiforme [GBMs]).
  • It was significantly associated with both longer overall and progression-free survival time in AA but not GBM patients.
  • CONCLUSION: Our results demonstrate that MGMT promoter hypermethylation is associated with longer survival time in patients with AA who were treated with surgery, radiotherapy, and ACNU-based chemotherapy but not in patients with GBM.
  • [MeSH-major] Brain Neoplasms / enzymology. Brain Neoplasms / therapy. DNA Methylation. Glioblastoma / enzymology. Glioblastoma / therapy. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Promoter Regions, Genetic / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Nimustine / therapeutic use. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14744281.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0S726V972K / Nimustine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


39. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol; 2000 Feb;18(4):708-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
  • PURPOSE: Little progress has been made in the treatment of adult high-grade gliomas over the last two decades, thus necessitating a search for novel therapeutic strategies.
  • Malignant gliomas are vascular or angiogenic tumors, which leads to the supposition that angiogenesis inhibition may represent a potentially promising strategy in the treatment of these tumors.
  • We present the results of a phase II trial of thalidomide, a putative inhibitor of angiogenesis, in the treatment of adults with previously irradiated, recurrent high-grade gliomas.
  • PATIENTS AND METHODS: Patients with a histologic diagnosis of anaplastic mixed glioma, anaplastic astrocytoma, or glioblastoma multiforme who had radiographic demonstration of tumor progression after standard external-beam radiotherapy with or without chemotherapy were eligible.
  • Patients were initially treated with thalidomide 800 mg/d with increases in dose by 200 mg/d every 2 weeks until a final daily dose of 1,200 mg was achieved.
  • One patient developed a grade 2 peripheral neuropathy after treatment with thalidomide for nearly a year.
  • Eight patients were alive more than 1 year after starting thalidomide, although almost all with tumor progression.
  • Changes in serum levels of basic fibroblastic growth factor (bFGF) were correlated with time to tumor progression and overall survival.
  • CONCLUSION: Thalidomide is a generally well-tolerated drug that may have antitumor activity in a minority of patients with recurrent high-grade gliomas.
  • Future studies will better define the usefulness of thalidomide in newly diagnosed patients with malignant gliomas and in combination with radiotherapy and chemotherapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Supratentorial Neoplasms / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Combined Modality Therapy. Constipation / chemically induced. Disease Progression. Female. Fibroblast Growth Factor 2 / blood. Follow-Up Studies. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Hypnotics and Sedatives / adverse effects. Male. Middle Aged. Peripheral Nervous System Diseases / chemically induced. Remission Induction. Survival Rate

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2000 Oct 1;18(19):3453 [11013292.001]
  • (PMID = 10673511.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor; 0 / Hypnotics and Sedatives; 103107-01-3 / Fibroblast Growth Factor 2; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


40. Lewandowicz GM, Harding B, Harkness W, Hayward R, Thomas DG, Darling JL: Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine. Eur J Cancer; 2000 Oct;36(15):1955-64
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to examine the range of sensitivity of a panel of short-term cultures derived from different types of malignant childhood brain tumours including medulloblastoma, ependymoma and glioblastoma multiforme to three cytotoxic drugs, lomustine (CCNU), vincristine (VCR) and procarbazine (PCB).
  • Short-term cell lines derived from ependymomas were considerably more resistant to VCR than other types of childhood brain tumours, while cultures derived from supratentorial primitive neuroectodermal tumour (PNET) displayed marked sensitivity to both lomustine and VCR.
  • Cultures from ependymomas, medulloblastoma and astrocytic gliomas had similar sensitivity to lomustine and PCB as cultures derived from adult malignant astrocytoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adult. Astrocytoma / drug therapy. Child. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Ependymoma / drug therapy. Female. Glioblastoma / drug therapy. Humans. Lomustine / therapeutic use. Male. Medulloblastoma / drug therapy. Procarbazine / therapeutic use. Tumor Cells, Cultured / drug effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11000577.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


41. Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Floeth F, Rommel F, Pan H, Hingorani VN, Puri RK: Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol; 2003 Aug-Sep;64(1-2):125-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.
  • PATIENTS AND METHODS: A total of 31 patients with histologically verified supratentorial grades 3 and 4 astrocytoma were studied.
  • Of these, 25 patients were diagnosed with glioblastoma multiforme (GBM) while six were diagnosed with anaplastic astrocytoma.
  • RESULTS: No drug-related systemic toxicity, as evident by lack of hematological or serum chemical changes, was apparent in any patients; treatment-related adverse effects were limited to the central nervous system.
  • No deaths were attributable to treatment.
  • Drug-related grade 3 or 4 toxicity was seen in 39% of patients in all dose groups and 22% of patients at the maximum tolerated dose of 6 microg/ml x 40 ml.
  • Gadolinium-enhanced magnetic resonance imaging of the brain showed areas of decreased signal intensity within the tumor consistent with tumor necrosis following treatment in many patients.
  • [MeSH-major] Astrocytoma / drug therapy. Bacterial Toxins / therapeutic use. Cerebellar Neoplasms / drug therapy. Exotoxins / therapeutic use. Glioblastoma / drug therapy. Interleukin-4 / therapeutic use. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies / analysis. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Safety. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2157-65 [10873064.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):899-904 [10854567.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):520-6 [8113865.001]
  • [Cites] Glia. 1995 Nov;15(3):244-56 [8586461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80 [8134351.001]
  • [Cites] Breast Cancer Res Treat. 1994;32(1):97-103 [7819590.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Cell Immunol. 1996 Jul 10;171(1):80-6 [8660841.001]
  • [Cites] Br J Cancer. 1997;75(6):822-8 [9062402.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):168-75 [11291041.001]
  • [Cites] Int J Cancer. 1994 Aug 15;58(4):574-81 [8056454.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1362-8 [9396606.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3357-63 [7614471.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1168-72 [10728667.001]
  • [Cites] J Neurosurg. 1995 Jun;82(6):1021-9 [7539062.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5631-7 [8971168.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):14-25 [11554386.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):326-34 [10690507.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6889-93 [8041715.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):316-9 [9927039.001]
  • [Cites] Cytokine. 2000 Nov;12(11):1656-61 [11052816.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1103-9 [11861389.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3649-53 [9721874.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8058-61 [11719427.001]
  • (PMID = 12952293.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Bacterial Toxins; 0 / Exotoxins; 0 / interleukin-4-Pseudomonas exotoxin; 207137-56-2 / Interleukin-4
  •  go-up   go-down


42. Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD: Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol; 2000 Nov 15;18(22):3862-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
  • PURPOSE: To determine the maximum-tolerated dose (MTD) of iodine-131 ((131)I)-labeled 81C6 antitenascin monoclonal antibody (mAb) administered clinically into surgically created resection cavities (SCRCs) in malignant glioma patients and to identify any objective responses with this treatment.
  • PATIENTS AND METHODS: In this phase I trial, newly diagnosed patients with malignant gliomas with no prior external-beam therapy or chemotherapy were treated with a single injection of (131)I-labeled 81C6 through a Rickham reservoir into the resection cavity.
  • Patients were observed for toxicity and response until death or for a minimum of 1 year after treatment.
  • None of the patients developed major hematologic toxicity.
  • Median survival for patients with glioblastoma multiforme and for all patients was 69 and 79 weeks, respectively.
  • CONCLUSION: The MTD for administration of (131)I-labeled 81C6 into the SCRC of newly diagnosed patients with no prior radiation therapy or chemotherapy was 120 mCi.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Glioma / radiotherapy. Immunotoxins / therapeutic use. Supratentorial Neoplasms / radiotherapy. Tenascin / immunology
  • [MeSH-minor] Adult. Aged. Animals. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Mice. Mice, Nude. Middle Aged. Survival Analysis. Tomography, Emission-Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078500.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / MO1 RR30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunotoxins; 0 / Tenascin
  •  go-up   go-down


43. López-Aguilar E, Sepúlveda-Vildósola AC, Rivera-Márquez H, Cerecedo-Díaz F, Valdés-Sánchez M, Delgado-Huerta S, Wanzke-del Angel V, Ramón-García G, Rodríguez-Jiménez H, Hernández-Contreras I, Santacruz-Castillo E, Romo-Rubio HA: Preirradiation ifosfamide, carboplatin and etoposide (ICE) for the treatment of high-grade astrocytomas in children. Childs Nerv Syst; 2003 Dec;19(12):818-23
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preirradiation ifosfamide, carboplatin and etoposide (ICE) for the treatment of high-grade astrocytomas in children.
  • BACKGROUND: Astrocytomas are the most common form of primary intracranial tumor; however, survival of patients with high-grade tumors has not changed much compared with that reported in the early 1970s.
  • OBJECTIVE. Our objective was to assess the efficacy, security, and survival rate of postoperative chemotherapy with ifosfamide, carboplatin, and etoposide (ICE) in pediatric patients with anaplastic astrocytomas (AA) and glioblastoma multiforme (GM).
  • The proposed treatment was four courses of chemotherapy with ICE followed by hyperfractionated radiotherapy, and then four more courses of ICE.
  • Patients were evaluated using MRI after surgery, after the second course of chemotherapy, and again after the last.
  • For supratentorial localization it was 92% at 60 months and 20% at 18 months for brain stem tumors.
  • Fourteen patients had a complete response and 9 died as a result of tumor progression.
  • CONCLUSIONS: Postoperative chemotherapy with ICE reduces the tumor size and increases the survival rate of pediatric patients with malignant astrocytomas with minimal toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / therapy. Central Nervous System Neoplasms / therapy
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Male. Prospective Studies. Radiotherapy / methods. Survival Rate

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2003 Dec;19(12):824 [14614569.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3878-84 [11051233.001]
  • [Cites] J Neurooncol. 2000;46(2):151-6 [10894368.001]
  • [Cites] Ann Neurol. 1987 Sep;22(3):355-64 [2823687.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):147-55 [11206010.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):416-20 [3574617.001]
  • [Cites] Br J Neurosurg. 1998 Jun;12(3):217-22 [11013683.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1458-65 [8336185.001]
  • [Cites] Neurosurgery. 1986 Oct;19(4):573-82 [3097567.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]
  • [Cites] J Neurosurg. 1970 Feb;32(2):127-44 [5411991.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2771-8 [2160318.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):920-7 [8039120.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Radiother Oncol. 2000 Aug;56(2):233-8 [10927143.001]
  • [Cites] Med Pediatr Oncol. 1993;21(1):49-53 [8381203.001]
  • [Cites] Med Pediatr Oncol. 1994;23(5):422-7 [8084309.001]
  • [Cites] Arch Med Res. 2000 Mar-Apr;31(2):186-90 [10880725.001]
  • (PMID = 14614568.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


44. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK, Cintredekin Besudotox Intraparenchymal Study Group: Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol; 2007 Mar 1;25(7):837-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Glioblastoma multiforme (GBM) is a devastating brain tumor with a median survival of 6 months after recurrence.
  • Convection-enhanced delivery (CED) is a locoregional-administration method leading to high-tissue concentrations with large volume of distributions.
  • PATIENTS AND METHODS: Three phase I clinical studies evaluated intracerebral CED of CB along with tumor resection.
  • The main objectives were to assess the tolerability of various concentrations and infusion durations; tissue distribution; and methods for optimizing delivery.
  • All patients underwent tumor resection followed by a single intraparenchymal infusion (in addition to the intraparenchymal one following resection), with a portion of patients who had a preresection intratumoral infusion.
  • The maximum tolerated intraparenchymal concentration was 0.5 microg/mL and tumor necrosis was observed at this concentration.
  • Postoperative catheter placement appears to be important for optimal drug distribution.
  • CB- and procedure-related adverse events were primarily limited to the CNS.
  • CED is a complex delivery method requiring catheter placement via a second procedure to achieve accurate catheter positioning, better drug distribution, and better outcome.
  • [MeSH-major] Drug Delivery Systems / methods. Exotoxins / administration & dosage. Glioma / drug therapy. Immunotoxins / administration & dosage. Interleukin-13 / administration & dosage. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Catheterization. Convection. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Tissue Distribution

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327604.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13
  •  go-up   go-down


45. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst; 2005 Jun 15;97(12):880-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 41 glioma patients, eight responded to treatment.
  • These associations were stronger and statistically significant among the 29 patients initially diagnosed with glioblastoma multiforme (P = .03 and P = .02, respectively).
  • Among six responders with sufficient tumor tissue, none had EGFRvIII mutations.
  • None of the 22 tumors with high levels of phosphorylated PKB/Akt responded to erlotinib treatment, whereas eight of the 18 tumors with low levels of phosphorylated PKB/Akt responded to erlotinib treatment (P < .001).
  • The level of phosphorylated PKB/Akt was also associated with time to progression (P < .001).
  • CONCLUSIONS: Among glioma patients, those with glioblastoma multiforme tumors who have high levels of EGFR expression and low levels of phosphorylated PKB/Akt had better response to erlotinib treatment than those with low levels of EGFR expression and high levels of phosphorylated PKB/Akt.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Jun 15;97(12):868-9 [15956643.001]
  • (PMID = 15956649.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097257; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NINDS NIH HHS / NS / P01 NS42927
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


46. Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M: Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol; 2008 Jun;31(3):300-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma.
  • The purpose of this review is to assess the palliative effect of re-irradiation in adult patients with recurrent supratentorial glioblastoma (GBM) previously treated with adjuvant or primary radiation therapy, with or without chemotherapy.
  • Data from more than 300 GBM patients (grade 3 anaplastic gliomas were excluded) demonstrate that re-irradiation yields 6-month PFS of 28% to 39% and 1-year overall survival of 18% to 48%, without additional chemotherapy (median value 26%).
  • Serious late toxicity was uncommon, especially after conventional treatment and fractionated stereotactic radiotherapy (FSRT).
  • In light of recent technological advances such as FSRT and intensity modulated radiotherapy, which permit maximal sparing of normal brain, re-treatment seems attractive, and deserves scientific validation.
  • Even fraction sizes of 3 to 5 Gy seem to be well tolerated in limited-volume recurrences as long as the total dose is limited to 30 to 35 Gy.
  • Salvage chemotherapy or targeted agents should be prospectively tested against re-irradiation alone.
  • [MeSH-major] Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Palliative Care. Quality of Life. Supratentorial Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525311.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


47. Tsien C, Moughan J, Michalski JM, Gilbert MR, Purdy J, Simpson J, Kresel JJ, Curran WJ, Diaz A, Mehta MP, Radiation Therapy Oncology Group Trial 98-03: Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys; 2009 Mar 1;73(3):699-708
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03.
  • PURPOSE: To evaluate in a Phase I trial the feasibility and toxicity of dose-escalated three-dimensional conformal radiotherapy (3D-CRT) concurrent with chemotherapy in patients with primary supratentorial glioblastoma (GBM).
  • All received 46 Gy in 2-Gy fractions to the first planning target volume (PTV(1)), defined as the gross tumor volume (GTV) plus 1.8 cm.
  • Four RT dose levels were evaluated: 66, 72, 78, and 84 Gy.
  • RESULTS: Acute and late Grade 3/4 RT-related toxicities were no more frequent at higher RT dose or with larger tumors.
  • There were no dose-limiting toxicities (acute Grade >or=3 irreversible central nervous system toxicities) observed on any dose level in either group.
  • On the basis of the absence of dose-limiting toxicities, dose was escalated to 84 Gy in both groups.
  • Late RT necrosis was noted at 66 Gy (1 patient), 72 Gy (2 patients), 78 Gy (2 patients), and 84 Gy (3 patients) in Group 1.
  • In Group 2, late RT necrosis was noted at 78 Gy (1 patient) and 84 Gy (2 patients).
  • Median time to RT necrosis was 8.8 months (range, 5.1-12.5 months).
  • CONCLUSIONS: Our study shows the feasibility of delivering higher than standard (60 Gy) RT dose with concurrent chemotherapy for primary GBM, with an acceptable risk of late central nervous system toxicity.

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1309-15 [2045305.001]
  • [Cites] J Neurosurg. 1991 Aug;75(2):177-80 [2072155.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):647-54 [8621289.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1535-43 [8608540.001]
  • [Cites] J Neurosurg. 1999 Aug;91(2):251-60 [10433313.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):511-9 [16168843.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):953-60 [16321763.001]
  • [Cites] Acta Neuropathol. 2006 Mar;111(3):197-212 [16463065.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1075-86 [16647222.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4738-46 [16899625.001]
  • [Cites] Am J Clin Oncol. 2007 Feb;30(1):32-7 [17278892.001]
  • [Cites] J Appl Clin Med Phys. 2007;8(2):47-60 [17592465.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):779-84 [10837964.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1351-8 [11121633.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1635-42 [11896114.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):810-21 [12095546.001]
  • [Cites] J Magn Reson Imaging. 2002 Oct;16(4):464-76 [12353260.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):826-36 [2585073.001]
  • (PMID = 18723297.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA081647; United States / NCI NIH HHS / CA / U24 CA081647-01; United States / PHS HHS / / 32115; United States / NCI NIH HHS / CA / CA21661; None / None / / U10 CA021661-24; United States / NCI NIH HHS / CA / U24 CA81647; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / CA37422; United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / U10 CA021661-24
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Steroids; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS96729; NLM/ PMC2913423
  •  go-up   go-down


48. Nieder C, Andratschke N, Wiedenmann N, Busch R, Grosu AL, Molls M: Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome? Strahlenther Onkol; 2004 Jul;180(7):401-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?
  • BACKGROUND AND PURPOSE: The publication of Radiation Therapy Oncology Group (RTOG) Study 83-02 in 1996 stimulated further investigations of altered fractionation, i. e., application of more than one fraction per day, in high-grade gliomas.
  • MATERIAL AND METHODS: To identify suitable trials, a Medline search was performed by use of the following key words: brain tumors/astrocytoma/glioma/high-grade glioma/malignant glioma/glioblastoma multiforme and accelerated radiotherapy/hyperfractionated radiotherapy/altered fractionation.
  • Studies in brain stem gliomas, pediatric patients and studies which achieved acceleration by radiosurgery, stereotactic radiotherapy, or brachytherapy rather than conventional external-beam treatment were not included.
  • The total number of 2-year survivors was then calculated for each treatment strategy and compared by use of the chi(2)-test.
  • In seven studies (658 patients), chemotherapy or radiosensitizers were not administered in addition to radiotherapy.
  • The others provide a very heterogeneous set of data, because a large variety of drugs and administration schedules was used.
  • Seven studies included patients with glioblastoma multiforme only, two were limited to patients with anaplastic gliomas.
  • Dose per fraction was 1.2-1.8 Gy in 17 studies and 1.9-2.65 Gy in four.
  • Overall treatment time was 12-31 days, except for one study.
  • Doses of 60-70 Gy do not appear to improve survival compared to 50-60 Gy.
  • Median survival was 10 months after radiotherapy alone (658 patients) and 11 months after combined treatment (756 patients).
  • However, prognostic factors such as tumor histology were not equally distributed and favor the combined-treatment group.
  • The studies of conventional radiotherapy plus chemotherapy or sensitizers included 1,115 patients with a median survival of 11 months (2-year survival rate 18.5%).
  • CONCLUSION: Altered fractionation shortens the overall treatment time for adult patients with supratentorial high-grade gliomas.
  • [MeSH-minor] Clinical Trials as Topic. Humans. Radiotherapy Dosage. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15241527.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 37
  •  go-up   go-down






Advertisement